Rigel Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Rigel Pharmaceuticals (South San Francisco, CA): 4 reconciled FDA prescription therapies, $95.1M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSouth San Francisco, CA
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$95.1M
2024 Medicare Part D Spend$77.8M
2024 Medicaid Spend$17.3M
California HCAI SB 17 Filings10 WAC filings (max 17.9% 2-yr change)